Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SABRATEK CORP (SBTK) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (47)	3/16/1999 9:26:00 AM
From: Mike	Read Replies (1) \| Respond to of 487

VLAD and others, What do you think about Sbtk going forward. Today the earnings are announced but the market has already stated what they think they will be. Not good. Market may have it all wrong but I dont think so on this one. Going forward the Rocap syringes are going to be needed to be reapproved. From what I have seen from the FDA lately many applications are being delayed (this has been the situation over the past three months). In addition, the FDA is taking it's time with companies that have run into problems (ala- BSX-Boston Scientific). Has anyone read the 10K as to what the picture looks like? I would expect if the company has it's ducks in a row will have big writeoffs or expenses this qtr. Lets hope many expenses are loaded into this dismal qtr so we can fly later. Is this a bad analogy or can we expect good things going forward? One last item is can anyone give a direct synopsis as to why the Rocap syringes were pulled? In the past I heard that it was both a probem that the company and the FDA created. The fault was not all on the part of SBTK. They were advised by the FDA incorrectly. Is this info correct? The reason why I ask is due to what maybe the timeframe for re-approval. The FDA does not look kindly on manipulators and many times will punish severly those who do. Not indicating that SBTK did but looking for info. Thanks, Mike